Accu-Chek Combo systemRoche-DIABETES-CARE-FDA-ACCU-CHEK-yh_original.jpg” style=”padding: 10px” title=”Accu-Chek Combo system” width=”300″ />

The US Food and Drug Administration (FDA) has cleared Roche’s Accu-Chek Combo system for insulin pump therapy as a treatment for diabetes.

The Accu-Chek Combo system features an insulin cartridge which can hold up to 315 units of insulin, as well as a full-colour display that provides blood glucose data, insulin dose information and pump settings.

The system combines a blood glucose metre with an insulin pump, which enables two-way wireless communication via bluetooth wireless technology.

The metre, which features a bolus advice function, allows users to operate the insulin pump remotely, easily calculate and deliver a right amount of insulin bolus without touching the pump.

Luc Vierstraete, Roche Diabetes Care head, said the launch of Accu-Chek Combo system demonstrates the company’s dedication to integrated diabetes management solutions, combining the technical components for blood glucose monitoring, data management and insulin delivery.

"The company said Accu-Chek Combo system is already available in several European and Asia-Pacific countries."

"This new system is designed to support insulin pump patients in managing diabetes easily and discreetly in their everyday lives," Vierstraete added.

Daniel O’ Day, Roche Diagnostics COO, said the company’s new insulin pump system will soon be available for people with diabetes in the US.

"With this clearance we are now looking forward to launching the second device in the US this year, after the successful clearance of the Accu-Chek Nano SmartView system in the first quarter," Day added.

"Both launches represent a significant milestone for our Diabetes Care business."

The company said Accu-Chek Combo system is already available in several European and Asia-Pacific countries, including France, Germany, the UK and Australia.

Image: Accu-Chek Combo system’s bolus advice function calculates and delivers the right amount of insulin bolus to diabetes patients. Photo courtesy of: F. Hoffmann-La Roche Ltd.